JOINT SAFETY AND NEUROLOGIC EVENTS WITH SUBCUTANEOUS TANEZUMAB OR ORAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN SUBGROUPS OF PATIENTS WITH OSTEOARTHRITIS FROM AN 80-WEEK PHASE 3 STUDY

著录项

• 来源
  《Osteoarthritis and cartilage》 |2021年第1期|共2页
• 作者

  Hunter D. J.; Radominski S.; Ulloa S. Rodriguez; Goranov I.; Radunovic G.; Chang C.; Pixton G.; Hickman A.; Fountaine R. J.; Brown M. T.; Viktrup L.; West C.;

  展开▼
• 作者单位

  Univ Sydney Sydney NSW Australia;

  Univ Fed Parana Curitiba Parana Brazil;

  Hosp Alta Complejidad Virgen Puerta Trujillo Peru;

  Univ Hosp Plovdiv Plovdiv Bulgaria;

  Univ Belgrade Inst Rheumatol Belgrade Serbia;

  Seoul Natl Univ Bundang Hosp Coll Med Seongnam Si South Korea;

  Pfizer Inc Morrisville NC USA;

  Pfizer Inc Groton CT 06340 USA;

  Pfizer Inc Groton CT 06340 USA;

  Pfizer Inc Groton CT 06340 USA;

  Eli Lilly &

  Co Indianapolis IN 46285 USA;

  Pfizer Inc Groton CT 06340 USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 骨科学（运动系疾病、矫形外科学）;
• 关键词